Trump Media to raise $2.5 billion to invest in bitcoin
(Reuters) -Trump Media and Technology Group will raise about $2.5 billion to invest in bitcoin, U.S. President Donald Trump's social media company said on Tuesday, as it looks to diversify its revenue.
The company is raising the funds by selling $1.5 billion in stock at its last closing price and $1 billion in convertible notes priced at a 35% premium, it said in a statement.
The bitcoin will be held on Trump Media's balance sheet alongside existing cash and short-term investments totaling $759 million as of the end of the first quarter. Crypto platforms Anchorage Digital and Crypto.com will provide custody for the bitcoin holdings.
"We view bitcoin as an apex instrument of financial freedom," Trump Media CEO Devin Nunes said, hailing the move as a "big step forward" in the company's plan to acquire "crown jewel assets consistent with America First principles."
Shares of the company behind Truth Social, a streaming and social media platform, were down 8%.
The move is part of a recent trend of public companies adding bitcoin and other cryptocurrencies to their balance sheets to capitalize on rising token prices as the Trump administration embraces digital assets.
Strategy - formerly known as MicroStrategy - has long been an aggressive investor in bitcoin and saw its shares soar more than six-fold last year, taking its market value to almost $94 billion. The company held $23.91 billion in crypto assets at the end of 2024.
Several other companies have tried to replicate Strategy's success, including GameStop and several biotech firms.
Last month, Cantor Fitzgerald announced that it would team up with Tether and SoftBank Group to launch Twenty One Capital, a bitcoin-buying entity that formed from a merger with blank-check vehicle Cantor Equity Partners. The combined vehicle is valued at $3.6 billion.
Trump Media has been exploring potential mergers and acquisitions as it aims to diversify into financial services.
Last month, it reached a binding agreement to launch various retail investment products, including crypto and exchange-traded funds aligned with Trump's policies.
The Trump family, long rooted in skyscrapers and country clubs, has opened multiple beachheads in crypto, quickly gaining hundreds of millions of dollars. Those other crypto forays include Trump NFTs, a meme coin, a stake in a newly formed bitcoin producer called American Bitcoin and World Liberty Financial, a decentralized crypto platform that also offers a stablecoin pegged to the U.S. dollar.
But the crypto push has attracted scrutiny from lawmakers, including Democratic Senator Elizabeth Warren, who last month asked the U.S. securities regulator about its plans to supervise ETFs due to be launched by Trump Media.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
39 minutes ago
- Business Insider
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy' Stocks
After a rocky start to the spring, Wall Street came roaring back in May. President Trump's softened tariff stance reignited demand for risk assets, triggering the market's biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Confident Investing Starts Here: Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. 'The effects of the stock market rally from the lows seen on April 8 appear to us to augur positively for investors practicing diversification and patience notwithstanding near-term uncertainties… We remain overweight US equities and do not ascribe to the view that US exceptionalism is fading,' Stoltzfus noted. Against this backdrop, Oppenheimer analyst Jay Olson has picked out his winners for the months ahead, zeroing in on two stocks in particular – including one with the potential to jump ~550% by this time next year. We checked in with the TipRanks database to see how the rest of Wall Street views these names. The verdict? Both picks carry Strong Buy consensus ratings across the board, with substantial upside potential. Let's take a closer look at the details. Voyager Therapeutics (VYGR) One company Oppenheimer is especially bullish on is Voyager Therapeutics, a clinical-stage biotech developing treatments for serious neurological diseases, including Alzheimer's disease and Friedreich's ataxia – both of which have limited therapeutic options. Voyager's lead clinical candidate is VY7523, a monoclonal antibody designed to target pathological tau (pTAU), a protein closely associated with the progression of Alzheimer's disease. Intended for early-stage intervention, the therapy has shown encouraging preclinical results. In mouse models, its murine surrogate demonstrated high selectivity for abnormal tau while sparing healthy tau and delivered strong efficacy in the P301S seeding model, a benchmark in Alzheimer's research. Voyager recently completed a Phase 1 single ascending dose (SAD) trial in healthy volunteers and has since launched a multiple ascending dose (MAD) trial in patients with early-stage AD. Topline SAD results were positive, showing that VY7523 was well tolerated across dose levels and achieved expected central nervous system exposure. Alongside its antibody-based approach, Voyager is also advancing a gene therapy pipeline powered by its proprietary TRACER capsid technology. These engineered capsids are designed to deliver therapeutic payloads directly to brain cells while minimizing off-target exposure in tissues such as the liver. Among these programs is VY1706, a tau-silencing gene therapy intended to suppress pTAU production in neurons for the treatment of Alzheimer's. At the 2025 AD/PD conference, Voyager presented encouraging non-human primate data showing that a single intravenous dose of VY1706 achieved dose-dependent, robust reductions in MAPT mRNA and tau protein across critical brain regions. An Investigational New Drug (IND) filing remains on track for 2026. The promise of Voyager's TRACER platform has attracted major pharmaceutical partners. Through deals with Neurocrine Biosciences, Novartis, and Alexion (a subsidiary of AstraZeneca), the company could earn up to $7.4 billion in milestone payments. The Neurocrine collaboration is already advancing gene therapy programs for Friedreich's ataxia and GBA1-related disorders, with IND filings expected in 2025 and clinical trials slated to begin in 2026. Voyager could receive up to $35 million in milestone payments tied to these near-term milestones. Currently trading at $2.74 per share, VYGR may be flying under the radar – but Oppenheimer's Jay Olson sees it as a compelling entry point. 'We remain enthusiastic about VYGR's unique platform and optionality, and believe VYGR is well-positioned to pursue tau-targeting with different approaches. VYGR's strong balance sheet with a cash runway into mid-2027 should offer stability… Additionally, we are encouraged by the positive preclinical data, external validation of the platform technology through multiple collaborations with industry leaders, a strong management team, and our optimistic long-term view on the gene therapy and CNS therapeutic area,' Olson said. To this end, Olson rates VYGR an Outperform (i.e., Buy), and his $18 price target implies room for a stunning 556% upside potential in the next 12 months. (To watch Olson's track record, click here) Tvardi Therapeutics (TVRD) The second name catching Oppenheimer's attention is Tvardi Therapeutics, another biopharmaceutical firm – but a newcomer to the public markets. The TVRD ticker began trading on the NASDAQ on April 16 of this year, following the completion of a merger between Tvardi Therapeutics and Cara Therapeutics. Following its public debut, Tvardi is now focused on developing breakthrough therapies for fibrosis-driven diseases. Its approach centers on targeting STAT3 (signal transducer and activator of transcription 3), a key protein in the STAT family, known for its pivotal role in numerous cellular processes. At the center of Tvardi's clinical efforts is TTI-101, an oral small-molecule STAT3 inhibitor that selectively targets pY-STAT3 within the SH2 domain. Tvardi is advancing TTI-101 as a treatment for both hepatocellular carcinoma (HCC) and idiopathic pulmonary fibrosis (IPF), two diseases marked by high unmet need and limited effective therapies. Early clinical results have been encouraging. In a first-in-human Phase 1 trial involving patients with advanced solid tumors, including HCC, TTI-101 was well tolerated with no dose-limiting toxicities. Pharmacodynamic data confirmed target engagement, with biopsies showing reduced levels of activated STAT3. Tvardi expects topline data from its ongoing Phase 1b/2 REVERT Liver Cancer clinical trial in HCC to be available in the first half of 2026. Meanwhile, building on insights from the same trial, Tvardi is also advancing the REVERT IPF Phase 2 study – a randomized, double-blind, placebo-controlled trial evaluating TTI-101, both as a monotherapy and in combination with nintedanib, in patients diagnosed with IPF within the past seven years. On May 27, 2025, the company announced that enrollment was complete, with topline results expected in the fourth quarter of this year. The potential of TTI-101, based on its earlier clinical trial results and optimistic forecasts for the current trials, has not gone unnoticed by Oppenheimer's Olson. The analyst is encouraged by the possible long-term returns, assuming success in both the trial and regulatory process. 'We see an underappreciated opportunity for lead asset TTI-101 as we forecast ~$1.2B peak risk-adjusted sales in 2040. Blinded Ph2a interim data suggest that TTI-101 could reverse IPF progression, thus supporting favorable differentiation from key competitors, with detailed Ph2a results expected in 2H25 serving as a potential valuable inflection point. In HCC, we believe TTI-101 offers a novel, mechanistically distinct approach, with interim Ph1b/2 data suggesting synergy in combination with SoC ahead of topline results in 1H26. We leverage our expertise in IPF and HCC to inform our analysis, and view TVRD as well-capitalized through key catalysts… Based on our DCF valuation of TVRD, we believe that its shares remain underappreciated,' Olson stated. With that backdrop, Olson rates TVRD an Outperform (i.e., Buy), alongside a $65 price target, suggesting a potential upside of 129% from current levels. Overall, this new stock has picked up 4 analyst reviews since it went public, and all are positive – making the Strong Buy consensus rating unanimous. TVRD is currently trading for $28.34, and its $50.75 average price target suggests that the shares have a 79% upside lying in wait for the year ahead. (See TVRD stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
41 minutes ago
- Yahoo
Oil finishes down on possible OPEC+ output hike
By Erwin Seba HOUSTON (Reuters) -U.S. crude futures fell on Friday as traders expected OPEC+ would decide on Saturday to boost oil output for July beyond previous forecasts. Brent crude futures settled down 25 cents, or 0.39%, at $63.90 a barrel. U.S. West Texas Intermediate crude finished down 15 cents, or 0.25%, at $60.79 a barrel, having earlier dropped more than $1 a barrel. The Brent July futures contract is due to expire on Friday. The more liquid August contract was down 71 cents, or 1.12%, at $62.64 a barrel. At these levels, the front-month benchmark contracts were headed for weekly losses over 1%. Prices dipped into negative territory after Reuters reported that OPEC+ may discuss an increase in July output larger than the 411,000 barrels per day (bpd) rise that the group decided on for May and June. "What OPEC+ is planning doesn't look particularly supportive for the oil market," said Matt Smith, Kpler's lead analyst for the Americas. The potential OPEC+ output hike comes as the global surplus has widened to 2.2 million bpd, likely necessitating a price adjustment to prompt a supply-side response and restore balance, said JPMorgan analysts in a note, adding that they expected prices to remain within the current range before easing into the high $50s by year-end. Phil Flynn, a senior analyst with Price Futures Group, said an online post on Truth Social by U.S. President Donald Trump that seemed to threaten more changes in tariff levels for Chinese imports also put pressure on crude prices. "Trump's Truth Social message on China failing to observe a truce on tariffs also combined with the Reuters headline to push prices down," Flynn said. Trump's tariffs were expected to remain in effect after a federal appeals court temporarily reinstated them on Thursday, reversing a trade court's decision a day earlier to put an immediate block on the sweeping duties. U.S. energy firms this week cut the number of oil and natural gas rigs operating for a fifth week in a row to the lowest since November 2021, energy services firm Baker Hughes said in its closely followed report on Friday. It was the first time since September 2023 that the number of rigs declined for five straight weeks. Baker Hughes said this week's decline put the total count down by 37 rigs, or 6%, from this time last year. Oil rigs fell by four to 461 this week, their lowest since November 2021, the company said. Gas rigs rose by one to 99.
Chicago Tribune
43 minutes ago
- Chicago Tribune
Iran has amassed even more near weapons-grade uranium, UN watchdog says
VIENNA — Iran has further increased its stockpile of uranium enriched to near weapons-grade levels, a confidential report by the U.N. nuclear watchdog said Saturday. In a separate report, the agency called on Tehran to urgently change course and comply with its years-long probe. The report comes at a sensitive time, as the administration of U.S. President Donald Trump seeks to reach a deal with Tehran to limit its nuclear program. The two sides have held several rounds of talks, so far without agreement. The report by the Vienna-based International Atomic Energy Agency — which was seen by The Associated Press — says that as of May 17, Iran has amassed 408.6 kilograms (900.8 pounds) of uranium enriched up to 60%. That's an increase of 133.8 kilograms (294.9 pounds) — or almost 50% — since the IAEA's last report in February. The 60% enriched material is a short, technical step away from weapons-grade levels of 90%. A report in February put this stockpile level at 274.8 kilograms (605.8 pounds). There was no immediate comment from Tehran on the new IAEA report. The IAEA report raised a stern warning, saying that Iran is now 'the only non-nuclear-weapon state to produce such material' — something the agency said was of 'serious concern.' Approximately 42 kilograms of 60% enriched uranium is theoretically enough to produce one atomic bomb, if enriched further to 90%, according to the watchdog. The IAEA report, a quarterly, also estimated that as of May 17, Iran's overall stockpile of enriched uranium — which includes uranium enriched to lower levels — stood at 9,247.6 kilograms (20,387.4 pounds). That's an increase of 953.2 kilograms (2,101.4 pounds) since February's report. Iran has maintained its nuclear program is for peaceful purposes only, but the IAEA chief, Rafael Mariano Grossi, has warned that Tehran has enough uranium enriched to near-weapons-grade levels to make 'several' nuclear bombs if it chose to do so. Iranian officials have increasingly suggested that Tehran could pursue an atomic bomb. U.S. intelligence agencies assess that Iran has yet to begin a weapons program, but has 'undertaken activities that better position it to produce a nuclear device, if it chooses to do so.' Israel said Saturday's report was a clear warning sign that 'Iran is totally determined to complete its nuclear weapons program,' according to a statement from Prime Minister Benjamin Netanyahu's office. It said IAEA's report 'strongly reinforces what Israel has been saying for years — the purpose of Iran's nuclear program is not peaceful.' It also added that Iran's level of enrichment 'has no civilian justification whatsoever' and appealed on the international community to 'act now to stop Iran.' It is rare for Netanyahu to make statements on Saturday, the Jewish day of rest, underlying the urgency with which he sees the matter. Grossi said Saturday that he 'reiterates his urgent call upon Iran to cooperate fully and effectively' with the IAEA's years long investigation into uranium traces discovered at several sites in Iran. The IAEA also circulated to member states on Saturday a second, 22-page confidential report, also seen by the AP, that Grossi was asked to produce following a resolution passed by the 35-member IAEA Board of Governors last November. In this so-called 'comprehensive report,' the IAEA said that Iran's cooperation with the agency has 'been less than satisfactory' when it comes to uranium traces discovered by IAEA inspectors at several locations in Iran that Tehran has failed to declare as nuclear sites. Western officials suspect that the uranium traces discovered by the IAEA could provide evidence that Iran had a secret military nuclear program until 2003. One of the sites became known publicly in 2018 after Netanyahu revealed it at the United Nations and called it a clandestine nuclear warehouse hidden at a rug-cleaning plant. Iran denied this but in 2019 IAEA inspectors detected the presence of manmade uranium particles there. After initially blocking IAEA access, inspectors were able to collect samples in 2020 from two other locations where they also detected the presence of manmade uranium particles. The three locations became known as Turquzabad, Varamin, and Marivan. A fourth undeclared location named as Lavisan-Shian is also part of the IAEA probe but IAEA inspectors never visited the site because it was razed and demolished by Iran after 2003. In Saturday's comprehensive report, the IAEA says that the 'lack of answers and clarifications provided by Iran' to questions the watchdog had regarding Lavisan-Shian, Varamin and Marivan 'has led the agency to conclude that these three locations, and other possible related locations, were part of an undeclared structured nuclear program carried out by Iran until the early 2000s and that some activities used undeclared nuclear material.' Saturday's comprehensive report could be a basis for possible further steps by European nations, leading to a potential escalation in tensions between Iran and the West. European countries could move to trigger snap-back sanctions against Iran that were lifted under the original 2015 nuclear deal ahead of October, when the deal formally expires. On Thursday, senior Iranian officials dismissed speculation about an imminent nuclear deal with the United States, emphasizing that any agreement must fully lift sanctions and allow the country's nuclear program to continue. The comments came a day after Trump said he has told Netanyahu to hold off on striking Iran to give the U.S. administration more time to push for a new deal with Tehran. Trump said on Friday that he still thinks a deal could be completed in the 'not too distant future.' 'They don't want to be blown up. They would rather make a deal,' Trump said of Iran. He added, 'That would be a great thing that we could have a deal without bombs being dropped all over the Middle East.'
